Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II neoadjuvant liposomal doxorubicin + docetaxel + trastuzumab + metformin in HER2-positive breast cancer
2014-002602-20Phase 2Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Aug 2014
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin, docetaxel, trastuzumab and metformin in breast cancer, sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoint: Pathologic complete response rate (pCR). Started Aug 2014; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2014-002602-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002602-20.